Cargando…
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
Background: There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to consider during real-world comparative analyses of F...
Autores principales: | Li, Edward, Schroader, Bridgette Kanz, Campbell, David, Campbell, Kim, Wang, Weijia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787317/ https://www.ncbi.nlm.nih.gov/pubmed/35127962 http://dx.doi.org/10.36469/001c.24564 |
Ejemplares similares
-
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis
por: McBride, Ali, et al.
Publicado: (2021) -
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021) -
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015) -
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018) -
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2015)